Skip to main content
Erschienen in: Journal of Neurology 3/2012

01.03.2012 | Original Communication

The impact of motor and non motor symptoms on health state values in newly diagnosed idiopathic Parkinson’s disease

verfasst von: James Shearer, Colin Green, Carl E. Counsell, John P. Zajicek

Erschienen in: Journal of Neurology | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Abstract

The aim of the study was to estimate health state utility values in newly diagnosed idiopathic Parkinson’s disease (PD) for use in the assessment of health-related quality-of-life (HRQL), and in the estimation of quality-adjusted life-years (QALYs). Data from 162 patients enrolled in a community-based incidence study of PD were used to estimate health state utility values. Self-report data from the EQ-5D, a generic measure of HRQL, were used to derive preference-based health state utility values. The impact of motor and non motor symptoms, and other clinical and demographic factors, on the derived EQ-5D health state values was examined in univariate and multivariate analyses. The mean health state utility value for recently diagnosed PD patients was estimated at 0.65 ± 0.27. Significant reductions in health state values were attributable to pain (−0.18), motor functioning (−0.16), depression (−0.12), and insomnia (−0.11). Depression had its greatest impact (−0.19) in patients in the less severe stages of PD (i.e. Hoehn Yahr stages ≤2.5). This study shows, through the presentation of QALY values, that there is scope to achieve significant health gains in newly diagnosed idiopathic PD patients via improved management of pain, depression and insomnia, alongside the treatment of primary motor symptoms.
Literatur
1.
Zurück zum Zitat Wickremaratchi MM, Perera D, O’Loghlen C et al (2009) Prevalence and age of onset of Parkinson’s disease in Cardiff: a community based cross sectional study and meta-analysis. J Neurol Neurosurg Psychiatry 80:805–807PubMedCrossRef Wickremaratchi MM, Perera D, O’Loghlen C et al (2009) Prevalence and age of onset of Parkinson’s disease in Cardiff: a community based cross sectional study and meta-analysis. J Neurol Neurosurg Psychiatry 80:805–807PubMedCrossRef
2.
3.
Zurück zum Zitat Dowding C, Shenton C, Salek S (2006) A review of the health-related quality of life and economic impact of Parkinson’s disease. Drugs Aging 23:693–721PubMedCrossRef Dowding C, Shenton C, Salek S (2006) A review of the health-related quality of life and economic impact of Parkinson’s disease. Drugs Aging 23:693–721PubMedCrossRef
4.
Zurück zum Zitat Rascol O, Payoux P, Ory F et al (2003) Limitations of current Parkinson’s disease therapy. Ann Neurol 53:S3–S12PubMedCrossRef Rascol O, Payoux P, Ory F et al (2003) Limitations of current Parkinson’s disease therapy. Ann Neurol 53:S3–S12PubMedCrossRef
5.
Zurück zum Zitat Soh S-E, Morris M, McGinley J (2011) Determinants of health-related quality of life in Parkinson’s disease. Parkinsonism Relat Disord 17:1–9PubMedCrossRef Soh S-E, Morris M, McGinley J (2011) Determinants of health-related quality of life in Parkinson’s disease. Parkinsonism Relat Disord 17:1–9PubMedCrossRef
6.
Zurück zum Zitat Gallagher D, Lees A, Schrag A (2010) What are the most important nonmotor symptoms in patients with Parkinson’s disease and are we missing them? Mov Disord 25:2493–2500PubMedCrossRef Gallagher D, Lees A, Schrag A (2010) What are the most important nonmotor symptoms in patients with Parkinson’s disease and are we missing them? Mov Disord 25:2493–2500PubMedCrossRef
7.
Zurück zum Zitat Canadian Agency for Drugs and Technologies in Health (2006) Guidelines for the economic evaluation of health technologies. Canadian Agency for Drugs and Technologies in Health, Ottawa Canadian Agency for Drugs and Technologies in Health (2006) Guidelines for the economic evaluation of health technologies. Canadian Agency for Drugs and Technologies in Health, Ottawa
8.
Zurück zum Zitat National Institute for Health and Clinical Excellence (2008) Guide to the methods of technology appraisal. National Institute for Health and Clinical Excellence, London National Institute for Health and Clinical Excellence (2008) Guide to the methods of technology appraisal. National Institute for Health and Clinical Excellence, London
9.
Zurück zum Zitat Pharmaceutical Benefits Advisory Committee. Guidelines for preparing submissions to the Pharmaceutical Benefits Advisory Committee. Barton: Australian Government Department of Health and Ageing; 2008 Pharmaceutical Benefits Advisory Committee. Guidelines for preparing submissions to the Pharmaceutical Benefits Advisory Committee. Barton: Australian Government Department of Health and Ageing; 2008
10.
Zurück zum Zitat Dorsey E, Meltzer D (2010) The economics of comparative effectiveness research. Neurology 75:492–493CrossRef Dorsey E, Meltzer D (2010) The economics of comparative effectiveness research. Neurology 75:492–493CrossRef
11.
Zurück zum Zitat Caslake R, Moore J, Gordon J et al (2008) Changes in diagnosis with follow-up in an incident cohort of patients with Parkinsonism. J Neurol Neurosurg Psychiatry 79:1202–1207PubMedCrossRef Caslake R, Moore J, Gordon J et al (2008) Changes in diagnosis with follow-up in an incident cohort of patients with Parkinsonism. J Neurol Neurosurg Psychiatry 79:1202–1207PubMedCrossRef
12.
Zurück zum Zitat Taylor K, Counsell C, Harris C et al (2006) Pilot study of the incidence and prognosis of degenerative Parkisonian disorders in Aberdeen, United Kingdom: methods and preliminary results. Mov Disord 21:976–982PubMedCrossRef Taylor K, Counsell C, Harris C et al (2006) Pilot study of the incidence and prognosis of degenerative Parkisonian disorders in Aberdeen, United Kingdom: methods and preliminary results. Mov Disord 21:976–982PubMedCrossRef
13.
Zurück zum Zitat Fahn S, Elton R (1987) UPDRS Development Committee. The Unified Parkinson’s Disease Rating Scale. In: Fahn S, Marsden C, Goldstein M, Calne D (eds) Recent developments in Parkinson’s disease. vol 2. Macmillan Healtcare Information, Florham Park, NJ, 153–163 Fahn S, Elton R (1987) UPDRS Development Committee. The Unified Parkinson’s Disease Rating Scale. In: Fahn S, Marsden C, Goldstein M, Calne D (eds) Recent developments in Parkinson’s disease. vol 2. Macmillan Healtcare Information, Florham Park, NJ, 153–163
14.
Zurück zum Zitat Goetz C, Poewe W, Rascol O et al (2004) Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: Status and recommendations The Movement Disorder Society Task Force on rating scales for Parkinson’s disease. Mov Disord 19:1020–1028PubMedCrossRef Goetz C, Poewe W, Rascol O et al (2004) Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: Status and recommendations The Movement Disorder Society Task Force on rating scales for Parkinson’s disease. Mov Disord 19:1020–1028PubMedCrossRef
15.
Zurück zum Zitat Folstein M, Folstein S, McHugh P (1975) “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189–198PubMedCrossRef Folstein M, Folstein S, McHugh P (1975) “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189–198PubMedCrossRef
16.
Zurück zum Zitat Mahieux F, Michelet D, Manifacier M-E et al (1995) Mini-mental Parkinson: First validation of a new bedside test constructed for Parkinson’s disease. Behav Neurol 8:15–22 Mahieux F, Michelet D, Manifacier M-E et al (1995) Mini-mental Parkinson: First validation of a new bedside test constructed for Parkinson’s disease. Behav Neurol 8:15–22
17.
Zurück zum Zitat Weintraub D, Oehlberg K, Katz I et al (2006) Test characteristics of the 15-item geriatric depression scale and Hamilton depression rating scale in Parkinson disease. Am J Geriatr Psychiatry 14:169–175PubMedCrossRef Weintraub D, Oehlberg K, Katz I et al (2006) Test characteristics of the 15-item geriatric depression scale and Hamilton depression rating scale in Parkinson disease. Am J Geriatr Psychiatry 14:169–175PubMedCrossRef
18.
Zurück zum Zitat Wade D, Collin C (1988) The Barthel ADL Index: A standard measure of physical disability? Int Disabil Stud. 10:64–67PubMedCrossRef Wade D, Collin C (1988) The Barthel ADL Index: A standard measure of physical disability? Int Disabil Stud. 10:64–67PubMedCrossRef
19.
20.
Zurück zum Zitat Schrag A, Selai C, Jahanshahi M et al (2000) The EQ-5D––a generic quality of life measure––is a useful instrument to measure quality of life in patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry 69:67–73PubMedCrossRef Schrag A, Selai C, Jahanshahi M et al (2000) The EQ-5D––a generic quality of life measure––is a useful instrument to measure quality of life in patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry 69:67–73PubMedCrossRef
21.
22.
Zurück zum Zitat Schrag A, Jahanshahi M, Quinn N (2000) How does Parkinson’s disease affect quality of life? A comparison with quality of life in the general population. Mov Disord 15:1112–1118PubMedCrossRef Schrag A, Jahanshahi M, Quinn N (2000) How does Parkinson’s disease affect quality of life? A comparison with quality of life in the general population. Mov Disord 15:1112–1118PubMedCrossRef
23.
Zurück zum Zitat Siderowf A, Ravina B, Glick H (2002) Preference-based quality-of-life in patients with Parkinson’s disease. Neurology 59:103–108PubMed Siderowf A, Ravina B, Glick H (2002) Preference-based quality-of-life in patients with Parkinson’s disease. Neurology 59:103–108PubMed
24.
Zurück zum Zitat Reuther M, Spottke E, Klotsche J et al (2007) Assessing health-related quality of life in patients with Parkinson’s disease in a prospective longitudinal study. Parkinsonism Relat Disord 13:108–114PubMedCrossRef Reuther M, Spottke E, Klotsche J et al (2007) Assessing health-related quality of life in patients with Parkinson’s disease in a prospective longitudinal study. Parkinsonism Relat Disord 13:108–114PubMedCrossRef
25.
Zurück zum Zitat Vossius C, Nilsen OB, Larsen JP (2009) Health state values during the first year of drug treatment in early-stage Parkinson’s disease: a prospective, population-based, cohort study. Drugs Aging 26:973–980PubMedCrossRef Vossius C, Nilsen OB, Larsen JP (2009) Health state values during the first year of drug treatment in early-stage Parkinson’s disease: a prospective, population-based, cohort study. Drugs Aging 26:973–980PubMedCrossRef
26.
Zurück zum Zitat Rahman S, Griffin H, Quinn N et al (2008) Quality of life in Parkinson’s disease: the relative importance of the symptoms. Mov Disord 23:1428–1434PubMedCrossRef Rahman S, Griffin H, Quinn N et al (2008) Quality of life in Parkinson’s disease: the relative importance of the symptoms. Mov Disord 23:1428–1434PubMedCrossRef
27.
Zurück zum Zitat Roh JH, Kim BJ, Jang JH et al (2009) The relationship of pain and health-related quality of life in Korean patients with Parkinson’s disease. Acta Neurol Scand 119:397–403PubMedCrossRef Roh JH, Kim BJ, Jang JH et al (2009) The relationship of pain and health-related quality of life in Korean patients with Parkinson’s disease. Acta Neurol Scand 119:397–403PubMedCrossRef
28.
Zurück zum Zitat Lee M, Walker R, Hildreth T et al (2006) A survey of pain in idiopathic Parkinson’s disease. J Pain Symptom Manag 32:462–469CrossRef Lee M, Walker R, Hildreth T et al (2006) A survey of pain in idiopathic Parkinson’s disease. J Pain Symptom Manag 32:462–469CrossRef
29.
Zurück zum Zitat Beiske AG, Loge JH, Ronningen A et al (2009) Pain in Parkinson’s disease: Prevalence and characteristics. Pain Jan 141:173–177 Beiske AG, Loge JH, Ronningen A et al (2009) Pain in Parkinson’s disease: Prevalence and characteristics. Pain Jan 141:173–177
30.
Zurück zum Zitat Forsaa E, Larsen J, Wentzel-Larsen T et al (2008) Predictors and course of health-related quality of life in Parkinson’s disease. Mov Disord 23:1420–1427PubMedCrossRef Forsaa E, Larsen J, Wentzel-Larsen T et al (2008) Predictors and course of health-related quality of life in Parkinson’s disease. Mov Disord 23:1420–1427PubMedCrossRef
31.
Zurück zum Zitat Qin Z, Zhang L, Sun F et al (2009) Health related quality of life in early Parkinson’s disease: impact of motor and non-motor symptoms, results from Chinese levodopa exposed cohort. Parkinsonism Relat Disord 15:767–771PubMedCrossRef Qin Z, Zhang L, Sun F et al (2009) Health related quality of life in early Parkinson’s disease: impact of motor and non-motor symptoms, results from Chinese levodopa exposed cohort. Parkinsonism Relat Disord 15:767–771PubMedCrossRef
32.
Zurück zum Zitat Li H, Zhang M, Chen L et al (2010) Nonmotor symptoms are independently associated with impaired health-related quality of life in Chinese patients with Parkinson’s disease. Mov Disord 25:2740–2746PubMedCrossRef Li H, Zhang M, Chen L et al (2010) Nonmotor symptoms are independently associated with impaired health-related quality of life in Chinese patients with Parkinson’s disease. Mov Disord 25:2740–2746PubMedCrossRef
33.
Zurück zum Zitat Schrag A (2006) Quality of life and depression in Parkinson’s disease. J Neurol Sci 248:151–157PubMedCrossRef Schrag A (2006) Quality of life and depression in Parkinson’s disease. J Neurol Sci 248:151–157PubMedCrossRef
34.
Zurück zum Zitat Chaudhuri KR, Martinez-Martin P, Brown RG et al (2007) The metric properties of a novel non-motor symptoms scale for Parkinson’s disease: results from an international pilot study. Mov Disord 22:1901–1911PubMedCrossRef Chaudhuri KR, Martinez-Martin P, Brown RG et al (2007) The metric properties of a novel non-motor symptoms scale for Parkinson’s disease: results from an international pilot study. Mov Disord 22:1901–1911PubMedCrossRef
Metadaten
Titel
The impact of motor and non motor symptoms on health state values in newly diagnosed idiopathic Parkinson’s disease
verfasst von
James Shearer
Colin Green
Carl E. Counsell
John P. Zajicek
Publikationsdatum
01.03.2012
Verlag
Springer-Verlag
Erschienen in
Journal of Neurology / Ausgabe 3/2012
Print ISSN: 0340-5354
Elektronische ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-011-6202-y

Weitere Artikel der Ausgabe 3/2012

Journal of Neurology 3/2012 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.